29 results about "Drug regimen" patented technology

The invention relates to the technical field of digital medical treatment and drug evaluation, in particular to an individualized drug curative effect and safety evaluation method and system based on digital twinborn and causal reinforcement learning. Individualized anti-fact prediction is realized through a patient digital twinning model, and potential curative effects and adverse event risks of different medication schemes can be evaluated on a single patient level. Meanwhile, an off-strategy causal reinforcement learning and dual-robust estimation method is adopted, the individualized value of a long-term sequential medication strategy is evaluated from observed real world data, and the preciseness of causal inference is improved; in addition, a curative effect-safety joint value function is constructed, curative effect benefits, safety risks and compliance cost are uniformly incorporated into the same decision framework, and multi-objective joint optimization is achieved; finally, an interpretability analysis report containing key features, value comparison and risk analysis is provided, the understanding and trust of clinicians on recommendation results are enhanced, and application and popularization in clinical practice are facilitated.

In particular, this disclosure provides technologies, including I-66 formulations, compositions, and methods, for treating various cancers. This disclosure provides technologies, such as formulations, dosages, and drug regimens, for treating conditions, disorders, or diseases, in particular certain types of cancer. In some embodiments, this disclosure provides high-purity I-66 active pharmaceutical ingredients. In some embodiments, this disclosure provides I-66 pharmaceutical products. In some embodiments, this disclosure provides I-66 formulations, which are liquid compositions in which I-66 has sufficiently high solubility and stability for clinical application.

To provide dosing regimens of GLP-1 analogs for the treatment of fat, obese, overweight, nonalcoholic fatty liver disease (NAFLD), and / or nonalcoholic steatohepatitis (NASH).SOLUTION: Administering to the subject a first effective amount of one or more first active ingredients selected from the group consisting of GLP-1 and GLP-1 analogs; A dosing regimen is provided, comprising: a first effective amount administered continuously, or intermittently at an interval between two consecutive administrations of six hours or less; and one or more second active ingredients selected from the group consisting of a second effective amount of GLP-I and a GLP-1 analog, administered to said subject once daily, twice daily, three times daily, or four times daily.SELECTED DRAWING: None

The present application relates to the technical field of digital medicine and drug evaluation, and particularly relates to an individualized drug efficacy and safety evaluation method and system based on digital twinning and causal reinforcement learning. Through a patient digital twinning model, individualized counterfactual prediction is realized, which can evaluate the potential efficacy and adverse event risk of different drug regimens at the individual patient level. Meanwhile, off-policy causal reinforcement learning and double robust estimation methods are used to evaluate the individualized value of long-term sequential drug strategies from observational real-world data, improving the rigor of causal inference. In addition, a combined efficacy-safety value function is constructed, which unifies efficacy benefits, safety risks, and compliance costs into the same decision framework, enabling multi-objective joint optimization. Finally, an interpretable analysis report is provided, including key features, value comparisons, and risk analyses, which enhances clinicians' understanding and trust in the recommended results, facilitating the application in clinical practice.

Disclosed are a system, techniques and processes for monitoring and modifying a drug treatment regimen when a user partakes in a ketogenic diet. The disclosed system obtains ketone level measurements of a user and indicates a user's adherence to the ketogenic diet as well as modifying a user's total daily dosage of a drug based on the user's following the ketogenic diet.

The invention provides a medical supervision platform. A patient personal information base and a pathology big database are established; the doctor inquires the patient according to the information of the patient information base and makes corresponding diagnosis; the supervision module compares and checks the diagnosis content of the proofreading doctor through big data; after checking, doctor diagnosis is input into a patient information base, and corresponding medical resources are allocated; the patient personal information base comprises basic information of patients, past medical history, medicine allergy history, examination results and uncomfortable symptoms, the pathology big database comprises disease names, disease indications, medicine principles and treatment modes, the platform can improve the accuracy and rationality of medical diagnosis, and by checking a medicine treatment scheme of a doctor, the medical diagnosis accuracy and rationality can be improved. And the treatment mode, the medicine type and the dosage are ensured to meet medical standards and patient requirements. The proofreading steps are helpful for reducing the risk of drug treatment and improving the treatment effect of patients.

A mesh network medication coordination system enables communication between intelligent injection devices, monitoring systems, patient devices, or healthcare provider devices to prevent adverse drug interactions in hospital settings. The system includes mesh network infrastructure supporting multiple networked devices, dosage measurement devices that directly measure or infer dosage administration including injection completion detection, medication volume measurement, administration timing data, or patient biometric responses, or a coordination module that coordinates medication administration timing across multiple devices. The system features drug interaction analysis capabilities, real-time monitoring of patient vital signs and medication effectiveness, alert generation for potential interactions and dosing conflicts, or data synchronization across all networked devices. This integrated approach optimizes dosing intervals, prevents conflicting medication schedules, synchronizes administration events, or maintains consistent medication administration data across the mesh network to enhance patient safety and treatment efficacy.

A method for developing novel drug therapies utilizing properties of existing drug therapies, the method comprising the steps of: developing a novel therapeutic mathematical model of a target biological network and synthesizing a drug therapy based on the novel therapeutic mathematical model. The novel therapeutic mathematical model is capable of generating novel therapeutic time-course progressions, which include time-course progression features found in existing therapeutic time-course progressions of existing therapeutic mathematical models of the target biological network. The time-course progression features can be correlated with the outcomes of the target biological network. Each new therapeutic intervention constant can be used to synthesize a drug regimen, and these drug regimens collectively constitute the novel drug therapy.

The invention relates to the technical field of information retrieval, in particular to an information retrieval method, a medium and equipment, which support the retrieval of three types of keywords, integrate multiple types of nodes in a graph, pre-construct a material relationship knowledge graph containing multi-dimensional nodes and association relationships, and combine visual output of a material information table and an association sub-graph, so that the information retrieval efficiency is improved. A logic chain between the medicine and each associated element is visually displayed, and associated query requirements of a user in multiple scenes can be met without cross-platform multiple retrieval; according to the method, authoritative data are integrated in the atlas construction process, so that association of drugs, treatment schemes and diseases has clinical reasonability and authority, meanwhile, association sub-atlases are extracted through association extension, false association and irrelevant information are effectively filtered, and the accuracy and reliability of retrieval results are improved; by outputting the first retrieval result page and the second retrieval result page in stages, the requirement of a user for rapidly screening target substances is met, deep detailed information can be provided, and the retrieval efficiency and the information depth are balanced.

The invention discloses an application of glutathione peroxidase 3 as a therapeutic target in preparation of a medicine for treating pulmonary fibrosis, and an application of a compound Ebselen in preparation of a medicine for treating pulmonary fibrosis. Through single cell and space transcriptomics analysis, it is found for the first time that expression of GPX3 in pulmonary fibrosis patients and model animal lung tissues is significantly reduced. In-vivo and in-vitro experiments prove that up-regulation of GPX3 expression can effectively inhibit fibroblast activation, migration, proliferation and oxidative stress and block a TGF-beta1 / Smad signal channel, so that collagen deposition and pulmonary fibrosis pathological change are relieved. Furthermore, a GPX3 simulant Ebselen is given by adopting an aerosol inhalation mode, is preferably loaded in liposome, and shows a remarkable anti-fibrosis effect in two mouse pulmonary fibrosis models induced by bleomycin and silicon dioxide. The invention provides a brand-new therapeutic target and a medicine scheme with clinical transformation potential for pulmonary fibrosis.

This invention relates to the pharmaceutical field, and more specifically to a drug used for the treatment of locally advanced, unresectable or metastatic colorectal cancer, and its use. Compared to a two-drug regimen of cintirimab + tucidinostat, the tripartite regimen of cintirimab + tucidinostat + IBI305 provided by this invention can significantly extend progression-free survival in patients with MSS / MSI-L locally advanced, unresectable or metastatic colorectal cancer. Furthermore, in terms of indicators such as ORR, PR, PD, NE, and DCR, patients with MSS / MSI-L locally advanced, unresectable or metastatic colorectal cancer can obtain significant benefits from the tripartite regimen of cintirimab + tucidinostat + IBI305.

A method for aiding the detection of drug effect using anaesthesia-induced patterns in an electroencephalogram (EEG), comprising: obtaining EEG data corresponding to one or more EEG signals of a patient under general anaesthesia measured using an EEG, wherein the one or more EEG signals are time-varying and comprise a time series of segments comprising at least a repeating first segment type and a repeating second segment type, wherein instances of segments corresponding to the first segment type alternate with instances of segments corresponding to the second segment type; and determining a signal metric comprising a series of time ordered metric datapoints, wherein each metric data point is determined based on: a comparison between at least two segments temporally associated with the metric point; and / or a comparison between at least two different measures of at least one segment temporally associated with the metric point, wherein the signal metric is a measurement of an effect of an anaesthetic drug regimen administered to the patient, and related methods and systems.

Multi-drug resistant tuberculosis (TB) is a major public health problem concerning about half a million cases each year. Patients hardly adhere to the current strict treatment consisting of more than 10,000 tablets over a 2-year period. There is a clear need for efficient and better-formulated medications. The inventors have previously shown that nanoparticles made of cross-linked poly-β-cyclodextrins (pβCD) are efficient vehicles for pulmonary delivery of powerful combinations of anti-TB drugs. Here, they report that in addition to be efficient drug carriers, pβCD nanoparticles are endowed with intrinsic antibacterial properties. Indeed, empty pβCD are able to impair M. tuberculosis (Mtb) establishment after pulmonary administration in mice. pβCD hamper colonisation of macrophages by Mtb by interfering with lipid rafts, without inducing toxicity. Moreover, pβCD provoke macrophage apoptosis leading to depletion of infected cells, thus creating a lung micro-environment detrimental to Mtb persistence. Taken together, the results suggest that materials made of cross-linked β-cyclodextrins (e.g. nanoparticles) loaded or not with antibiotics play an antibacterial action by its own and could be used as carrier in drug regimen formulations effective against TB.

The application discloses a urology use split type urine collecting bag, which comprises a first urine collecting area, a second urine collecting area, a third urine collecting area and a fourth urine collecting area, a first tearable strip is arranged between the first urine collecting area and the second urine collecting area and the fourth urine collecting area, a second tearable strip is arranged between the third urine collecting area and the second urine collecting area and the fourth urine collecting area, the first tearable strip and the second tearable strip are gathered and connected to a center point of the urine collecting bag, an adjusting part is detachably connected to an outer wall surface of the urine collecting bag, the adjusting part comprises a disc and a rotating motor embedded in the center of the disc, an adjusting fixing piece is connected to an output end of the rotating motor, and the adjusting fixing piece is respectively in contact with the first urine collecting area, the second urine collecting area, the third urine collecting area and the fourth urine collecting area, so as to adjust the positions of the first urine collecting area, the second urine collecting area, the third urine collecting area and the forth urine collecting area. The application is convenient for observing the urine volume of a patient and formulating a drug treatment scheme suitable for the individual, and effectively avoids the problems of poor experience of the patient and waste of medical resources caused by replacing the urine collecting bag due to multiple times of taking and placing urine.

The present application provides a set of complete innovative technical solutions from target discovery to treatment intervention for the immune escape and drug resistance recurrence problems existing in the clinical treatment of multiple myeloma (MM). It is found that Siglec7 is mainly highly expressed on the surface of NK cells, and the proportion and expression intensity of Siglec7 positive NK cells are significantly higher than those of complete remission and non-tumor controls; further, Siglec7 monoclonal antibody is prepared, and when the anti-Siglec7+CD38 monoclonal antibody (such as daratumumab) is used, a significant synergistic anti-tumor effect can be produced in vitro and in vivo. The technical solution completely constructs the research and development chain of "marker discovery-target verification-drug development-treatment application", and provides a new target, specific antibody drug and innovative combined drug regimen for the precise diagnosis, prognosis and especially immunotherapy of refractory and relapsed patients with multiple myeloma, which has great clinical transformation value and market prospect.

The invention discloses an application of total glucosides of paeony in treatment of psoriasis in combination with Jikukiespecially and calcipotriol, and relates to the technical field of medical treatment, a psoriasis-like mouse model induced by imiquimod is established, and the synergistic treatment effect of a triple therapy of total glucosides of paeony, Jikukiespecially and calcipotriol is verified; the application comprises the step of jointly applying the three medicines according to a specific dosage. The triple therapy can improve erythema, scale and infiltration symptoms of psoriasis-like skin lesion, effectively reduce the area and severity index score of psoriasis, and inhibit the protein and mRNA expression level of key proinflammatory cytokines in skin lesion tissues; compared with a single drug or a combination of two drugs, the triple therapy provided by the invention shows a better treatment effect, and a new and effective drug combination scheme is provided for clinical treatment of psoriasis.

The present invention relates to AST-3424 for treatment of a cancer patient resistant to an immune checkpoint inhibitor, and relates to a treatment method for a human malignant tumor, and particularly to a method for an AKR1C3-activated anticancer prodrug compound AST-3424 to treat a cancer patient resistant to an immune checkpoint inhibitor, and a pharmaceutical use. Disclosed are a method for using an AST-3424 monotherapy or combination immunotherapy regimen to treat a cancer / tumor patient resistant / insensitive to an immunotherapy regimen, a use of the AST-3424 monotherapy or combination immunotherapy regimen in preparation of a drug for treating the cancer / tumor patient resistant / insensitive to the immunotherapy regimen, and a method for cross-administration of AST-3424 and the immunotherapy regimen to treat the cancer / tumor patient, wherein the immunotherapy regimen is preferably selected from among drug therapy regimens comprising the immune checkpoint inhibitor / an immune cell therapy.

The invention discloses an intelligent evaluation method and system for drug curative effect and toxicity based on multi-modal pathological data fusion, and relates to the technical field of drug evaluation systems. Comprising the steps that biological characteristic data under the action of a target drug is collected, a multi-modal characteristic vector is constructed, and the biological characteristic data comprises an animal experiment data source, an in-vitro experiment data source and a public database or existing research data. According to the method, quantitative analysis is carried out on changes of multi-modal features in the time dimension, features reflecting focus improvement, immune activation and curative effect stability are fused, and curative effect indexes are constructed; meanwhile, weighted integration is carried out on characteristics reflecting tissue damage, immune imbalance and toxicity related effects, toxicity indexes are constructed, and on the basis, multi-dimensional comprehensive judgment of the drug action effect is realized by establishing a combined evaluation system of curative effect and toxicity, and quality grades of different drug schemes are divided in a visual mode.

The present application relates to the technical field of biological medicine, in particular to an antifungal drug composition based on (1,3)-beta-D-glucan synthase inhibitor and application thereof. In vivo and in vitro experiments prove that the combination of endogenous antibacterial peptide LL-37 and (1,3)-beta-D-glucan synthase inhibitor (such as caspofungin, micafungin, anidulafungin, rezafungin and albaconazole) shows significant synergistic inhibitory effect on multiple drug-resistant pathogenic fungi such as Candida albicans and Candida auris. Since free antibacterial peptides are easily degraded by proteases, the present application is based on the synergistic killing mechanism of breaking the network barrier of fungal cell wall and assisting endogenous defense peptide to target cell membrane, and ingeniously uses the "antibacterial peptide LL-37 expression promoter" to actively up-regulate the synthesis of host natural peptides, which provides a new drug regimen for clinical treatment of deep fungal infection.

The utility model provides a micro-fluidic chip, which relates to the technical field of biological detection and comprises a substrate, a plurality of flow channels are formed between the substrate and a cover plate, one end of each flow channel is communicated with a dosing port and is provided with a first electromagnetic valve, and the other end of each flow channel is provided with a second electromagnetic valve; the multiple sets of three-dimensional culture cavities are sequentially arranged between the first electromagnetic valve and the second electromagnetic valve in the extending direction of the corresponding flow channels, and the positions, flowing through the three-dimensional culture cavities, of the flow channels protrude towards the cover plate and are in an arc shape; each three-dimensional culture cavity is provided with an input pipeline facing the first electromagnetic valve and an outlet facing the second electromagnetic valve, the input pipeline and the outlet are communicated with the flow channel, and the diameter of the input pipeline is smaller than that of the outlet. The method has the beneficial effects that a plurality of drug treatment schemes and combination strategies can be evaluated at the same time, high-throughput continuous multi-day culture of micro-tumors is realized, and the method can be applied to the fields of clinical individualized medication scheme formulation, new drug research and development, basic medical research and the like, so that precise treatment of lung cancer is promoted.

The present application relates to a kind of recombinant complement protein and the application in the preparation of anti-leukemia drugs, belong to biological medicine technical field;The present application discloses that single drug treatment, i.e. injection recombinant C1QBP protein has significant effect in the treatment of acute leukemia, can significantly inhibit the proliferation of leukemia cells in hematopoietic system bone marrow, spleen, peripheral blood, while inhibiting the infiltration of leukemia cells in extramedullary organs (skin, etc.), thereby reducing the whole body tumor load, significantly prolonging the survival period of leukemia mouse.Recombinant C1QBP protein is combined with clinical first-line chemotherapy regimen, has synergistic effect, compared with single use chemotherapy drug has stronger effect of inhibiting the proliferation of leukemia cells, can significantly prolong the survival period of leukemia mouse, has played the effect of attenuated and synergistic effect.The present application first proves that complement C1Q binding protein has the effect of treating leukemia, and provides preparation method and combined drug regimen, has higher clinical conversion prospect and application value.

The clinical curative effect of the colistin is severely weakened by the global transmission of the colistin resistance gene MCR-1. In order to deal with the severe drug resistance problem of daily benefit, the invention provides the application of the eucalyptus leaf essential oil as a polymyxin synergist. In-vitro experiments such as a bouillon microdilution chessboard method, a time-sterilization curve and a scanning electron microscope prove that the folium eucalypti essential oil can effectively recover the antibacterial activity of the polymyxin on MCR-1 positive enterobacter; a greater wax moth infection model experiment is further applied to prove that the drug combination scheme has a good in-vivo protection effect on MCR-1 positive bacterium infection. Therefore, the eucalyptus leaf essential oil is combined with the polymyxin as a synergist, and important support can be provided for developing a novel treatment strategy aiming at MCR-1 positive enterobacter infection.

The invention relates to application of emodin in resisting carbapenem drug-resistant klebsiella pneumoniae, and belongs to the technical field of medicines. The invention provides an application of emodin in preparation of a product for resisting carbapenem antibiotic drug-resistant klebsiella pneumoniae, and the emodin is combined with KPC-2 type carbapenem enzyme generated by the carbapenem antibiotic drug-resistant klebsiella pneumoniae to inhibit the activity of KPC-2 hydrolysis of carbapenem antibiotics, so that the bactericidal effect of the antibiotics is enhanced. The research shows that the emodin can be combined with the TRP-105 site and the THR-237 site of the KPC-2 protein to change the functional group composition and the secondary structure of the KPC-2 protein, so that the hydrolytic activity of the KPC-2 is inhibited, and the bactericidal effect of antibiotics is enhanced. According to the invention, the medicinal value of the emodin is expanded, and meanwhile, a brand new drug combination scheme is provided for treating carbapenem drug-resistant klebsiella pneumoniae infection.

This invention relates to the field of artificial intelligence technology, specifically to an intelligent medical diagnostic engine based on a large AI model. The engine includes an auxiliary diagnostic module that collects patient electronic medical records, medical images, and other data, and uses ensemble learning methods to predict auxiliary outcomes; a drug recommendation module that analyzes drug recommendation data using the large AI model to predict the potential efficacy and side effects of new drugs; and a surgical simulation module that combines virtual reality technology to construct a surgical environment and human body model. This invention enables rapid processing and analysis of large amounts of medical data through auxiliary diagnosis, shortening diagnostic time and reducing unnecessary invasive examinations and misdiagnosis. Drug recommendation integrates patients' genetic, physiological, and pathological multi-omics data to provide patients with personalized drug treatment plans and doctors with comprehensive and accurate diagnostic evidence and treatment recommendations. Furthermore, by accurately simulating real surgical scenarios, including mechanical and optical properties, it provides doctors and medical students with a more realistic training experience.

The invention, which belongs to the technical field of intelligent medication, discloses an intelligent medication scheme recommendation method based on big data, and the method specifically comprises the following steps: collecting daily activity characteristics and medical record data of a patient; according to the diagnosis information and the inspection result, screening drugs which are consistent in indications and have no taboo components to obtain a primarily screened drug set; determining life scene categories according to occupational types and work and rest laws of the patients, and calculating life scene interference values of the medicines based on a preset interference coefficient library; screening a reference group similar to the target patient, and calculating an expected curative effect score of each drug by analyzing a re-diagnosis record of the reference group; and normalizing the interference value and the curative effect score, weighting according to a preset weight to obtain a comprehensive adaptation degree, and selecting the drug with the highest adaptation degree to output. According to the invention, the daily life scene of the patient is fused into the medication decision, the fusion of clinical effectiveness and life feasibility is realized, and the medication compliance is improved.

The invention discloses application of aucubin in treatment of sexual precocity. According to the application, a precocious puberty mouse model is firstly constructed, in a Balb / c mouse precocious puberty model induced by a low dose of BPA, aucubin intervention can significantly down-regulate expression of key genes KISS1 and GnRH1 in hypothalamic development regulation and central development regulation, reduce the level of sex hormone in peripheral blood, delay ovarian development, and inhibit hypothalamic development regulation and central development regulation. The vaginal opening time (body surface marks of rodent model sexual development initiation) is delayed, so that sexual precocious puberty is treated. The invention provides a new medicine scheme for treating precocious puberty, provides a new thought for research and development of precocious puberty treatment medicines, and expands the application range of aucubin.

The present invention pertains to the field of nutraceuticals, specifically to a synergistic nutraceutical composition designed to improve cardio-metabolic health. The composition, comprising berberine, anthocyanin(s), and astaxanthin, is intended to regulate aberrant metabolic biomarkers, including hyperglycemia, hypertriglyceridemia, elevated low-density lipoprotein (LDL) cholesterol, increased blood pressure, enhanced platelet aggregation, elevated serum transaminase activity and hypoadiponectinemia. This invention is particularly applicable to the therapeutic management of cardiometabolic pathologies, including Type 2 Diabetes Mellitus (T2DM), arterial hypertension, dyslipidemia, atherosclerosis, obesity, metabolic syndrome, non-alcoholic fatty liver disease (NAFLD), cerebrovascular accidents (stroke), and coronary artery disease, through the modulation of systemic metabolic homeostasis and by providing potential adjunctive efficacy alongside established pharmacotherapeutic regimens.

This invention provides a drug for preventing and treating intrauterine adhesions and its application, belonging to the field of biomedical technology. The drug comprises a pharmaceutically acceptable carrier and enhanced mesenchymal stem cells treated with a specific pretreatment culture medium. The pretreatment culture medium contains a stimulating component composed of Panax notoginseng saponin R1, melatonin, and tartary buckwheat polypeptides added to the basal culture medium. Through the significant synergistic effect of the combined use of these three components, this invention effectively enhances the tolerance of mesenchymal stem cells to the hypoxic-hypoglycemic microenvironment and strengthens their paracrine function. Experimental results show that these enhanced stem cells can significantly downregulate fibrosis markers such as α-SMA and COL1A1, inhibit the process of endometrial fibrosis, and significantly increase endometrial thickness and glandular number, promoting structural reconstruction and functional repair of damaged endometrium, providing a highly effective new drug regimen for the clinical treatment of intrauterine adhesions.